Compare Otis Worldwide Corp (OTIS) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Otis Worldwide Corp vs Tango Therapeutics Inc. — how do they compare? Otis Worldwide Corp trades at $69.11 (market cap $25.76B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Otis Worldwide Corp is far larger — about 6.9× Tango Therapeutics Inc.'s market cap, and Otis Worldwide Corp pays a 2.6% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Otis Worldwide Corp for 66 Days and Tango Therapeutics Inc. for 0 Days on average.
| OTIS | TNGX | |
|---|---|---|
Market Cap | $25.76B | $3.75B |
Volume | 6,407,907 | 9,619,106 |
Sector | Industrials | Health |
52-Week High | $93.62 | $32.90 |
52-Week Low | $64.05 | $7.50 |
Typical Hold Time | 66 Days | 0 Days |
Enterprise Value | $33.80B | $2.77B |
Dividend Yield | 2.6% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Otis Worldwide trades at $69.11, up 3.54% today but near its 52-week low amid bearish technical signals and recent earnings misses. The company maintains stable revenue around $14.4B with a 10.17% net margin, though service margins face pressure from labor costs. Analyst consensus is mixed with a $87 price target, while institutional investors show varied positioning through recent acquisitions and sales.
The stock presents a defensive opportunity given its dominant elevator service franchise, but near-term upside is limited by margin pressures and China demand uncertainty. Key risks include execution on service margin expansion and macroeconomic headwinds affecting new equipment orders.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
